Acadia misses mark alzheimers concludes phase 3 absolutely worth pursuing

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 16:02 UTC

Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3 program.

science

Sources

• T2Acadia misses mark alzheimers concludes phase 3 absolutely worth pursuingFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 16:02